
NVIDIA Announces New Partnerships with IQVIA, Illumina, Mayo Clinic, and Arc Institute
NVIDIA announced a new partnership to transform the $10 trillion healthcare and life sciences industry by accelerating drug discovery, enhancing genomic research, and pioneering advanced healthcare services through the use of agentic and generative AI.
The convergence of AI, accelerated computing, and biological data is transforming healthcare into a massive technology industry. IQVIA and Illumina are key leaders in the healthcare industry,Mayo ClinicArc Institute is leveraging the latest NVIDIA technology to develop solutions that improve human health.
Those solutions include AI agents that reduce administrative burdens and accelerate clinical trials, AI models that learn from biological instruments to advance drug discovery and digital pathology, and physical AI robots for surgery, patient monitoring, and operations.
AI Agents, AI Devices, and AI Robots will create hundreds of billions of dollars of AI factory opportunities, with $3 trillion worth of work to meet the growing demand.
NVIDIA's Vice President of Healthcare, Kimberly Powell, said, "We are very pleased to be working with NVIDIA to help bring the newest technologies to the market.
"AI offers a unique opportunity to advance healthcare and life sciences by providing tools to help detect diseases earlier and develop new treatments faster, and combining NVIDIA's AI and accelerated computing capabilities with the expertise of industry leaders will usher in a new era of medical and biological innovation that will improve patient outcomes around the world. will usher in a new era of medical and biological innovation that will improve patient outcomes worldwide."
AI Foundry Services Enhance Drug Discovery and Medical Device Development
IQVIA is a global leader in the business of providing clinical research services, commercial insights and healthcare intelligence to the life science and healthcare industries.NVIDIA AI FoundryBy using the service, IQVIA builds custom infrastructure models based on over 64 petabytes of information and a wealth of expertise.
IQVIA also,NVIDIA NIM™.Microservices andNVIDIA BlueprintWe are developing an agent-based AI solution using NVIDIA AI Enterprise software, including This solution will reduce the time it takes for research, clinical development, and new treatments.
In addition, IQVIA has played a pioneering role in the responsible use of AI, ensuring that AI capabilities are based on privacy, regulatory compliance, and patient safety.
Bhavik Patel, President of Commercial Solutions at IQVIA, said, "We are very pleased to be working with IQVIA to help our customers achieve their business goals.
This is a major leap forward in IQVIA's approach to applying AI to healthcare and life sciences. By combining IQVIA's industry-leading capabilities and decades of experience in artificial intelligence with NVIDIA's advanced AI technology, we are pleased to build new solutions powered by AI agents trained with world-class medical information and optimized for life science workflows. We are pleased to be building a new solution powered by AI agents trained with world-class medical information and optimized for life science workflows. This collaboration advances IQVIA's mission to accelerate customer innovation and therapies to market."
Illumina and NVIDIA Accelerate Next-Generation Genomic Breakthroughs
Illumina, a global leader in DNA sequencing and informatics technologies, is collaborating with NVIDIA to explore next-generation genomics for drug discovery and human health.
The partnership will enable Illumina to leverage NVIDIA's accelerated computing and AI toolset for its multi-omics analysis software and workflow.
For researchers, pharmaceutical companies, and other life science customers, it will be easier to analyze and gain insights from the human genome.
Illumina will provide DRAGEN analysis software that leverages NVIDIA accelerated computing within the Illumina Connected Analytics platform. This integration will extend DRAGEN accessibility to all locations around the world where NVIDIA computing platforms are present.
Over the past five years, single-cell and spatial genomics have revolutionized drug discovery as cells have been analyzed and understood to unprecedented levels. To further expand the genomics market and enable breakthroughs in target identification, clinical development, and biomarker discovery, NVIDIA and Illumina are collaborating to develop new biological infrastructure models as well as to advance Advancing Multi-Omics Data Analysis.
R&D community included in the NVIDIA AI Enterprise software platform NVIDIA RAPIDS™. Accelerated Data Science Software andNVIDIA BioNeMo™ platform's generative AI models, as well as unique dataset fine-tuning capabilities and for spatial cellular imaging workflows.MONAIThe integration of the "MEDLINE" system makes it easy to take advantage of the wealth of genomic data available.
Illumina and NVIDIA will work to make these tools available on the Illumina Connected Analytics platform.
Steven Barnard, CTO of Illumina, stated
Illumina is revolutionizing the understanding of disease by combining the power of AI with multi-omics data. Illumina's expertise in genomics data and analysis, combined with NVIDIA's powerful AI platform, will help pharmaceutical and biotech companies analyze their own multi-omics data to discover innovative insights and improve the success rate of developing life-saving treatments for patients. to improve the success rate of developing life-saving treatments for patients."
AI-driven digital pathology at Mayo Clinic
Pathology is an important technique that clinicians use to diagnose and determine treatments for many types of cancer and other serious and complex health conditions, but the process has long been a time-consuming manual task.
Built upon an autonomous robotics lab and advanced imaging technology, the Mayo Clinic Digital Pathology platform provides a rich and unique data set consisting of 20 million whole slide images and 10 million associated patient records to enable the creation of the underlying model and enables the creation of the foundational model.
Mayo Clinic and NVIDIA will significantly accelerate the development of the next generation of pathology infrastructure models.
The Mayo Clinic is a newNVIDIA DGX™ B200 SystemThe system will be based on the NVIDIA Blackwell architecture and will feature 1.4TB of GPU memory per system. which is based on the NVIDIA Blackwell architecture and has 1.4TB of GPU memory per system, making it ideal for processing digital disease medicine whole slide data sets. The system will also adopt NVIDIA's MONAI medical imaging platform.
Mayo Clinic and NVIDIA are pioneering this research as a cornerstone for future AI applications in drug discovery and personalized diagnosis and treatment. mayo Clinic and NVIDIA will leverage Mayo's clinical and AI expertise, NVIDIA Cosmos Nemotron visual language models, NIM microservices, and will further expand this collaboration to enhance personalization of healthcare and provide predictive and efficient treatment strategies.
Open Science Biology AI Model Scaled by Arc Institute
Based in Palo Alto, California, the Arc Institute is a research institute that combines biology and machine learning, working with NVIDIA to develop and deliver powerful AI models and tools to advance biomedical discovery.
Arc's biology and machine learning researchers will work with NVIDIA engineers to expand the potential of fundamental biological models that can generalize across different modalities, such as DNA, RNA, and proteins, to advance applications in drug discovery, synthetic biology of varying complexity, and disease and evolution research.
As part of this collaboration, NVIDIA is providing Arc Institute with expertise in large-scale model development. This includes,NVIDIA DGX™ Cloud NVIDIA NIM microservices and Blueprint, as well as the NVIDIA BioNeMo platform for easy-to-use, optimized training, running on NVIDIA NIM.
*This presentation was released on January 13, 2025 U.S. time.Press ReleaseThis is an excerpt from the
About NVIDIA
NVIDIA (NASDAQ: NVDA) is a global leader in accelerated computing.
| name of company | NVIDIA |
| Location | 13F ATT New Tower, 2-11-7 Akasaka, Minato-ku, Tokyo |
| representative | Masataka Osaki |
| uniform resouce locator | https://www.nvidia.com/ja-jp |









